The Clostridium difficile (C.diff) incidence in the inflammatory bowel disease (IBD) population is approximately 7%, which is three times more than the general population. According to the Canadian gastroenterology guidelines, all patients who have symptoms suggesting a flare up of their disease should be tested for C.diff. The goal of this study was to determine if a systematic screening is required for all patients considering the potential delays in treating the IBD flare. Aims: The primary outcome was to determine the incidence of C.diff infection in these patients. The secondary outcomes were to determine the rate of screening for C.diff during the first days of hospitalisation, the delay in treatment of the IBD caused by the C.diff investigation and to determine if an early IBD flare treatment worsened the C.diff infection. Methods: This is a descriptive and retrospective study with a source population including all IBD patients that were hospitalised in the gastroenterology service of the CHUM Hospital between 2014 and 2017. These patients were initially hospitalised for clinical symptoms suggesting an IBD flare. Results: 429 patients constituted our source population. 216 patients were included in our study according to the inclusion and exclusion criteria (total of 269 hospitalisations). The mean age was 49 years old and 39,4% (n=106) were men. 55,7% (n=150) had Crohn's disease, 39,8% (n=107) had ulcerative colitis (UC) and 4,5% (n=12) an indeterminate colitis. The screening test for C.diff was prescribed in 67,3% of cases (n=181). 14 of these tests were positive, corresponding to an incidence of 7,73% (UC: 8 cases out of 86 tested (9,30%); CD: 3 cases out of 87 tested (3,45%); indeterminate colitis: 3 cases out of 9 tested (33,30%). The location of the 3 positives C.diff cases in patients with Crohn was pancolic (n=2) and ileocolic (n=1). 8 of these 14 patients who tested positive for C.diff already had started a treatment for the IBD flare when the screening result was obtained. These patients had a mean duration of hospitalisation of 5,4 days (σ=2,77) vs 14,5 days (σ=10,97) for those who had not started any IBD treatment. The treatment of the IBD was delayed by a mean of 0,5 days in the patients with a negative screening test. Conclusions: The incidence of C.difficile in this study population was 7,73%, which is similar to what is reported in the literature for other IBD populations. This high incidence reinforces the need to screen all IBD patients that consult for symptoms Downloaded from https://academic.oup.com/jcag/article-abstract/2/Supplement_2/240/5381285 by guest on 17 January 2020
suggestive of an IBD flare, particularly those with ulcerative colitis and indeterminate colitis.
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